Prostate development and carcinogenesis

International Review of Cytology

Volumn 227, Issue , 2003, Pages 65-130

  Wong, Y C ^a,b   Wang, X H ^a   Ling, M T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Carcinogenesis; Epithelial Mesenchymal interaction; Paracrine factors; Prostate development

Indexed keywords

FUCOSYLTRANSFERASE; GROWTH FACTOR; HOMEODOMAIN PROTEIN; HOX PROTEIN; PROSAPOSIN; PROTEIN AS3; PROTEIN HOXD 13; PROTEIN NKX3.1; PROTEIN P63; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL CELL; ANIMAL TISSUE; BRANCHING MORPHOGENESIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOLOGY; EMBRYO DEVELOPMENT; EMBRYOLOGY; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GENE MUTATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEREDITY; HOMEOSTASIS; HORMONAL CARCINOGENESIS; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENCHYME CELL; MESODERM; METABOLISM; MOUSE; NONHUMAN; PARACRINE SIGNALING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE TUMOR; REVIEW; SMOOTH MUSCLE; STROMA CELL; TESTIS DEVELOPMENT; TESTOSTERONE RELEASE; TUMOR SUPPRESSOR GENE;

EID: 0141818099     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7696(03)01008-8     Document Type: Article

References (340)

1. Aaltomaa, S., Lipponen, P., Eskelinen, M., Ala-Opas, M., and Kosma, V. M. (1999). Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 39, 8-15.
2. Adams, J. Y., Leav, I., Lau, K. M., Ho, S. M., and Pflueger, S. M. V. (2002). Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate. Prostate 52, 69-81.
3. Akanni, A., and Abul-Hajj, Y. J. (1997). Estrogen-nucleic acid adducts: Reaction of 3,4-estrone-o-quinone radical anion with deoxyribonucleosides. Chem. Res. Toxicol. 10, 760-766.
4. Alani, R. M., Hasskarl, J., Grace, M., Hernandez, M. C., Israel, M. A., and Munger, K. (1999). Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc. Natl. Acad. Sci. USA 96, 9637-9641.
5. Aprikian, A. G., Bazinet, M., Plante, M., Meshref, A., Trudel, C., Aronson, S., Nachabe, M., Peloquin, F., Dessureault, J., and Narod, S., et al. (1995). Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J. Urol. 154, 404-406.
6. Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H. M., Bredesen, D. E., Pasqualini, R., and Ruoslahti, E. (2002). Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA 99, 1527-1531.
7. Armstrong, B., and Doll, R. (1975). Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int. J. Cancer 15, 617-631.
8. Arnold, J. T., and Isaacs, J. J. (2002). Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr. Relat. Cancer 9, 61-73.
9. Arrick, B. A., Lopez, A. R., Elfman, F., Ebner, R., Damsky, C. H., and Derynck, R. (1992). Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J. Cell Biol. 118, 715-726.
10. Balbay, M. D., Pettaway, C. A., Kuniyasu, H., Inoue, K., Ramirez, E., Li, E., Fidler, I. J., and Dinney, C. P. (1999). Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin. Cancer Res. 5, 783-789.
11. Bardelli, A., and Comoglio, P. M. (1997). Scatter factor receptors are key players in a unique multistep program leading to invasive growth. Ciba Found. Symp. 212, 133-144.
12. Bassing, C. H., Yingling, J. M., Howe, D. J., Wang, T., He, W. W., Gustafson, M. L., Shah, P., Donahoe, P. K., and Wang, X. F. (1994). A transforming growth factor beta type I receptor that signals to activate gene expression. Science 263, 87-89.
13. Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., and Weintraub, H. (1990). The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59.
14. Berry, R., Schroeder, J. J., French, A. J., McDonnell, S. K., Peterson, B. J., Cunningham, J. M., Thibodeau, S. N., and Schaid, D. J. (2000). Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am. J. Hum. Genet. 67, 82-91.
15. Berthon, P., Valeri, A., Cohen-Akenine, A., Drelon, E., Paiss, T., Wohr, G., Latil, A., Millasseau, P., Mellah, I., Cohen, N., Blanche, H., Bellane-Chantelot, C., Demenais, F., Teillac, P., Le Duc, A., de Petriconi, R., Hautmann, R., Chumakov, I., Bachner, L., Maitland, N. J., Lidereau, R., Vogel, W., Fournier, G., Mangin, P., and Cussenot, O., et al. (1998). Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.243. Am. J. Hum. Genet. 62, 1416-1424.
16. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R., Abate-Shen, C., and Shen, M. M. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977.
17. Birchmeier, C., and Gherardi, E. (1998). Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8, 404-410.
18. Birchmeier, W., Brinkmann, V., Niemann, C., Meiners, S., DiCesare, S., Naundorf, H., and Sachs, M. (1997). Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found. Symp. 212, 230-240.
19. Bonkhoff, H. (1996). Role of the basal cells in premalignant changes of the human prostate: A stem cell concept for the development of prostate cancer. Eur. Urol. 30, 201-205.
20. Bonkhoff, H. (1998). Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 8, 18-22.
21. Bonkhoff, H., Fixemer, T., Hunsicker, I., and Remberger, K. (2001). Progesterone receptor expression in human prostate cancer: Correlation with tumor progression. Prostate 48, 285-291.
22. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., and Allred, D. C. (1993). p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53, 3369-3373.
23. Bosland, M. C., and Prinsen, M. K. (1990). Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2′-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res. 50, 691-699.
24. Bowen, C., Bubendorf, L., Voeller, H. J., Slack, R., Willi, N., Sauter, G., Gasser, T. C., Koivisto, P., Lack, E. E., Kononen, J., Kallioniemi, O. P., and Gelmann, E. P. (2000). Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60, 6111-6115.
25. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. (1996). An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 56, 3814-3822.
26. Brown, L. F., Yeo, K. T., Berse, B., Morgentaler, A., Dvorak, H. F., and Rosen, S. (1995). Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J. Urol. 154, 576-579.
27. Bruchovsky, N., Lesser, B., Van Doorn, E., and Craven, S. (1975). Hormonal effects on cell proliferation in rat prostate. Vitam. Horm. 33, 61-102.
28. Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A. F., Lerman, M. I., Zabarovsky, E., White, M., and Minna, J. D. (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 93, 691-699.
29. Burton, J. L., Oakley, N., and Anderson, J. B. (2000). Recent advances in the histopathology and molecular biology of prostate cancer. BJU Int. 85, 87-94.
30. Carcamo, J., Zentella, A., and Massague, J. (1995). Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol. Cell Biol. 15, 1573-1581.
31. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
32. Carter, B. S., Bova, G. S., Beaty, T. H., Steinberg, G. D., Childs, B., Isaacs, W. B., and Walsh, P. C. (1993). Hereditary prostate cancer: Epidemiologic and clinical features. J. Urol. 150, 797-802.
33. Cerhan, J. R., Parker, A. S., Putnam, S. D., Chiu, B. C., Lynch, C. F., Cohen, M. B., Torner, J. C., and Cantor, K. P. (1999). Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol. Biomarkers Prev. 8, 53-60.
34. Chamberlain, N. L., Driver, E. D., and Miesfeld, R. L. (1994). The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22, 3181-3186.
35. Chan, J. M., Stampfer, M. J., Ma, J., Gann, P., Gaziano, J. M., Pollak, M., and Giovannucci, E. (2002). Insulin-like growth factor-I factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. 94, 1099-1106.
36. Chang, H. L., Gillett, N., Figari, I., Lopez, A. R., Palladino, M. A., and Derynck, R. (1993). Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 53, 4391-4398.
37. Chevalier, S., Defoy, I., Lacoste, J., Hamel, L., Guy, L., Begin, L. R., and Aprikian, A. G. (2002). Vascular endothelial growth factor and signaling in the prostate: More than angiogenesis. Mol. Cell Endocrinol. 189, 169-179.
38. Choo, C. K., Ling, M. T., Chan, K. W., Tsao, S. W., Zheng, Z., Zhang, D., Chan, L. C., and Wong, Y. C. (1999). Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 40, 150-158.
39. Commoner, B., Vithayathil, A. J., Dolara, P., Nair, S., Madyastha, P., and Cuca, G. C. (1978). Formation of mutagens in beef and beef extract during cooking. Science 201, 913-916.
40. Cooke, P. S., Young, P., and Cunha, G. R. (1991a). Androgen receptor expression in developing male reproductive organs. Endocrinology 128, 2867-2873.
41. Cooke, P. S., Young, P., Hess, R. A., and Cunha, G. R. (1991b). Estrogen receptor expression in developing epididymis, efferent ductules, and other male reproductive organs. Endocrinology 128, 2874-2879.
42. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., and Francke, U., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139.
43. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285.
44. Cui, L., Takahashi, S., Tada, M., Kato, K., Yamada, Y., Kohri, K., and Shirai, T. (2000). Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: Results with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PHIP) and 3,2′-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity. Jpn. J. Cancer Res. 91, 52-58.
45. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. (1993). Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7, 1541-1550.
46. Cunha, G. R. (1984). Androgenic effects upon prostatic epithelium are mediated via trophic influences from stroma. In (F. A. Kimbell, A. E. Buhl, and D. B. Carter, Eds.) "New Approaches to the Study of Benigh Prostatic Hyperplasia," pp. 81-102, A. R. Liss, New York.
47. Cunha, G. R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74, 1030-1044.
48. Cunha, G. R., and Chung, L. W. (1981). Stromal-epithelial interactions - I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J. Steroid Biochem. 14, 1317-1324.
49. Cunha, G. R., and Young, P. (1991). Inability of Tfm (testicular feminization) epithelial cells to express androgen-dependent seminal vesicle secretory proteins in chimeric tissue recombinants. Endocrinology 128, 3293-3298.
50. Cunha, G. R., Reese, B. A., and Sekkingstad, M. (1980). Induction of nuclear androgen-binding sites in epithelium of the embryonic urinary bladder by mesenchyme of the urogenital sinus of embryonic mice. Endocrinology 107, 1767-1770.
51. Cunha, G. R., Fujii, H., Neubauer, B. L., Shannon, J. M., Sawyer, L., and Reese, B. A. (1983). Epithelial-mesenchymal interactions in prostatic development. I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J. Cell Biol. 96, 1662-1670.
52. Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., Higgins, S. J., and Sugimura, Y. (1987). The endocrinology and developmental biology of the prostate. Endocr. Rev. 8, 338-362.
53. Cunha, G. R., Alarid, E. T., Turner, T., Donjacour, A. A., Boutin, E. L., and Foster, B. A. (1992a). Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J. Androl. 13, 465-475.
54. Cunha, G. R., Battle, E., Young, P., Brody, J., Donjacour, A., Hayashi, N., and Kinbara, H. (1992b). Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epithelial Cell Biol. 1, 76-83.
55. Cunha, G. R., Hayward, S. W., Dahiya, R., and Foster, B. A. (1996). Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat. (Basel) 155, 63-72.
56. Cunha, G. R., Hayward, S. W., and Wang, Y. Z. (2002). Role of stroma in carcinogenesis of the prostate. Differentiation 70, 473-485.
57. Cussenot, O., and Valeri, A. (2001). Heterogeneity in genetic susceptibility to prostate cancer. Eur. J. Intern. Med. 12, 11-16.
58. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25, 315-319.
59. Daughaday, W. H., and Rotwein, P. (1989). Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10, 68-91.
60. Davies, M. A., Kim, S. J., Parikh, N. U., Dong, Z., Bucana, C. D., and Gallick, G. E. (2002). Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res. 8, 1904-1914.
61. De Marzo, A. M., Nelson, W. G., Meeker, A. K., and Coffey, D. S. (1998). Stem cell features of benign and malignant prostate epithelial cells. J. Urol. 160, 2381-2392.
62. Desprez, P. Y., Hara, E., Bissell, M. J., and Campisi, J. (1995). Suppression of mammary epithelial cell differentiation by the helix-loop-helix protein Id-1. Mol. Cell Biol. 15, 3398-3404.
63. Desprez, P. Y., Lin, C. Q., Thomasset, N., Sympson, C. J., Bissell, M. J., and Campisi, J. (1998). A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. Mol. Cell Biol. 18, 4577-4588.
64. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255,989-991.
65. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355.
66. Djavan, B., Waldert, M., Seitz, C., and Marberger, M. (2001). Insulin-like growth factors and prostate cancer. World J. Urol. 19, 225-233.
67. Dong, J. T., Sipe, T. W., Hyytinen, E. R., Li, C. L., Heise, C., McClintock, D. E., Grant, C. D., Chung, L. W., and Frierson, H. F., Jr. (1998). PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17, 1979-1982.
68. Donjacour, A. A., and Cunha, G. R. (1993). Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice. Endocrinology 132, 2342-2350.
69. Eid, M. A., Kumar, M. V., Iczkowski, K. A., Bostwick, D. G., and Tindall, D. J. (1998). Expression of early growth response genes in human prostate cancer. Cancer Res. 58, 2461-2468.
70. Emmert-Buck, M. R., Vocke, C. D., Pozzatti, R. O., Duray, P. H., Jennings, S. B., Florence, C. D., Zhuang, Z., Bostwick, D. G., Liotta, L. A., and Linehan, W. M. (1995). Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 55, 2959-2962.
71. English, H. F., Santen, R. J., and Isaacs, J. T. (1987). Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11, 229-242.
72. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
73. Ferrer, F. A., Miller, L. J., Lindquist, R., Kowalczyk, P., Laudone, V. P., Albertsen, P. C., and Kreutzer, D. L. (1999). Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54, 567-572.
74. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70.
75. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C., and Greenberg, N. M. (1997). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325-3330.
76. Foster, B. A., Evangelou, A., Gingrich, J. R., Kaplan, P. J., DeMayo, F., and Greenberg, N. M. (2002). Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 70, 624-632.
77. Foster, C. S., Dodson, A., Karavana, V., Smith, P. H., and Ke, Y. (2002). Prostatic stem cells. J. Pathol. 197, 551-565.
78. Fujita, H., Koshida, K., Keller, E. T., Takahashi, Y., Yoshimito, T., Namiki, M., and Mizokami, A. (2002). Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53, 232-240.
79. Geck, P., Szelei, J., Jimenez, J., Sonnenschein, C., and Soto, A. M. (1999). Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: A new suppressor candidate on chromosome 13, in the BRCA2-Rb1 locus. J. Steroid Biochem. Mol. Biol. 68, 41-50.
80. Gibbs, M., Standford, J. L., McIndoe, R. A., Jarvik, G. P., Kolb, S., Goode, E. L., Chakrabarti, L., Schuster, E. F., Buckley, V. A., Miller, E. L., Brandzel, S., Li, S., Hood, L., and Ostrander, E. A. (1999). Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am. J. Hum. Genet. 64, 776-787.
81. Gilroy, D. W., and Colville-Nash, P. R. (2000). New insights into the role of COX 2 in inflammation. J. Mol. Med. 78, 121-129.
82. Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., and Greenberg, N. M. (1996). Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56, 4096-4102.
83. Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, H.-F. J., and Weber, M. J. (1999). Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59, 279-284.
84. Giordano, S., Di Renzo, M. F., Narsimhan, R. P., Cooper, C. S., Rosa, C., and Comoglio, P. M. (1989). Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 4, 1383-1388.
85. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Dahl, D., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. (1997). The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA 94, 3320-3323.
86. Gmyrek, G. A., Walburg, M., Webb, C. P., Yu, H. M., You, X., Vaughan, E. D., Vande-Woude, G. F., and Knudsen, B. S. (2001). Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am. J. Pathol. 159, 579-590.
87. Gooderham, N. J., Zhu, H., Lauber, S., Boyce, A., and Creton, S. (2002). Molecular and genetic toxicology of 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat. Res. 506-507, 91-99.
88. Goodman, A. H. (2000). Why genes don't count (for racial differences in health). Am. J. Public Health 90, 1699-1702.
89. Graff, J. R. (2002). Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin. Ther. Targets 6, 103-113.
90. Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., Vessella, R. L., and Neubauer, B. L. (2000). Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kipl expression. J. Biol. Chem. 275, 24500-24505.
91. Grasso, A. W., Wen, D., Miller, C. M., Rhim, J. S., Pretlow, T. G., and Kung, H. J. (1997). ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 15, 2705-2716.
92. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. (1995). Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92, 3439-3443.
93. Grossfeld, G. D., Hayward, S. W., Tlsty, T. D., and Cunha, G. R. (1998). The role of stroma in prostate carcinogenesis. Endocr. Relat. Cancer 5, 253-270.
94. Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G., and Mukhtar, H. (2000). Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73-78.
95. Haggstrom, S., Wikstrom, P., Bergh, A., and Damber, J. E. (1998). Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 36, 71-79.
96. Haggstrom, S., Lissbrant, I. F., Bergh, A., and Damber, J. E. (1999). Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J. Urol. 161, 1620-1625.
97. Hahn, D., Simak, R., Steiner, G. E., Handisurya, A., Susani, M., and Marberger, M. (2000). Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J. Urol. 164, 506-510.
98. Hanks, S. K., and Quinn, A. M. (1991). Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members. Methods Enzymol. 200, 38-62.
99. Hara, E., Uzman, J. A., Dimri, G. P., Nehlin, J. O., Testori, A., and Campisi, J. (1996). The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. Dev. Genet. 18, 161-172.
100. Harper, M. E., Glynne-Jones, E., Goddard, L., Thurston, V. J., and Griffiths, K. (1996). Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br. J. Cancer 74, 910-916.
101. Haughney, P. C., Hayward, S. W., Dahiya, R., and Cunha, G. R. (1998). Species-specific detection of growth factor gene expression in developing murine prostatic tissue. Biol. Reprod. 59, 93-99.
102. Hayes, R. B., de Jong, F. H., Raatgever, J., Bogdanovicz, J., Schroeder, F. H., van der, M. P., Oishi, K., and Yoshida, O. (1992). Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur. J. Cancer Prev. 1, 239-245.
103. Hayward, S. W., and Cunha, G. R. (2000). The prostate: Development and physiology. Radiol. Clin. North Am. 38, 1-14.
104. Hayward, S. W., Dahiya, R., Cunha, G. R., Bartek, J., Deshpande, N., and Narayan, P. (1995). Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev. Biol. Anim. 31, 14-24.
105. Hayward, S. W., Cunha, G. R., and Dahiya, R. (1996). Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann. N. Y. Acad. Sci. 784, 50-62.
106. Hayward, S. W., Rosen, M. A., and Cunha, G. R. (1997). Stromal-epithelial interactions in the normal and neoplastic prostate. Br. J. Urol. 79(Suppl. 2), 18-26.
107. Hayward, S. W., Grossfeld, G. D., Tlsty, T. D., and Cunha, G. R. (1998a). Genetic and epigenetic influences in prostatic carcinogenesis (review). Int. J. Oncol. 13, 35-47.
108. Hayward, S. W., Haughney, P. C., Rosen, M. A., Greulich, K. M., Weier, H. U., Dahiya, R., and Cunha, G. R. (1998b). Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 63, 131-140.
109. He, W. W., Kumar, M. V., and Tindall, D. J. (1991). A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-feminized mouse. Nucleic Acids Res. 19, 2373-2378.
110. He, W. W., Sciavolino, P. J., Wing, J., Augustus, M., Hudson, P., Meissner, P. S., Curtis, R. T., Shell, B. K., Bostwick, D. G., Tindall, D. J., Gelmann, E. P., Abate-Shen, C., and Carter, K. C. (1997). A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43, 69-77.
111. Hellawell, G. O., Turner, G. D., Davies, D. R., Poulsom, R., Brewster, S. F., and Macaulay, V. M. (2002). Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62, 2942-2950.
112. Hla, T., and Neilson, K. (1992). Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89, 7384-7388.
113. Ho, S. M., and Roy, D. (1994). Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett. 84, 155-162.
114. Hodgson, A. V., Ayala-Torres, S., Thompson, E. B., and Liehr, J. G. (1998). Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis 19, 2169-2172.
115. Howell, M. A. (1974). Factor analysis of international cancer mortality data and per capita food consumption. Br. J. Cancer 29, 328-336.
116. Hsieh, J. T., Luo, W., Song, W., Wang, Y., Kleinerman, D. I., Van, N. T., and Lin, S. H. (1995). Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res. 55, 190-197.
117. Hsing, A. W., Gao, Y. T., Wu, G., Wang, X., Deng, J., Chen, Y. L., Sesterhenn, I. A., Mostofi, F. K., Benichou, J., and Chang, C. (2000a). Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res. 60, 5111-5116.
118. Hsing, A. W., Tsao, L., and Devesa, S. S. (2000b). International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60-67.
119. Hsing, A. W., Reichardt, J. K., and Stanczyk, F. Z. (2002). Hormones and prostate cancer: Current perspectives and future directions. Prostate 52, 213-235.
120. Huang, J., Powell, W. C., Khodavirdi, A. C., Wu, J., Makita, T., Cardiff, R. D., Cohen, M. B., Sucov, H. M., and Roy-Burman, P. (2002). Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res. 62, 4812-4819.
121. Huggins, C., and Hodges, C. V. (1941). Studies on prostatic cancer. The effect of castration, or estrogen and of androgen interaction on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297.
122. Hughes-Fulford, M., Chen, Y., and Tjandrawinata, R. R. (2001). Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22, 701-707.
123. Humphrey, P. A., Zhu, X., Zarnegar, R., Swanson, P. E., Ratliff, T. L., Vollmer, R. T., and Day, M. L. (1995). Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386-396.
124. Hunter, T. (1995). Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 80, 225-236.
125. Huss, W. J., Hanrahan, C. F., Barrios, R. J., Simons, J. W., and Greenberg, N. M. (2001). Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res. 61, 2736-2743.
126. Igdoura, S. A., Rasky, A., and Morales, C. R. (1996). Trafficking of sulfated glycoprotein-1 (prosaposin) to lysosomes or to the extracellular space in rat Sertoli cells. Cell Tissue Res. 283, 385-394.
127. Imaida, K., Sano, M., Tamano, S., Asamoto, M., Ogawa, K., Futakuchi, M., and Shirai, T. (2001). Organ dependent enhancement of rat 3,2′ -dimethyl-4-aminobiphenyl (DMAB) carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP): Positive effects on the intestine but not the prostate. Carcinogenesis 22, 1295-1299.
128. Irvine, R. A., Yu, M. C., Ross, R. K., and Coetzee, G. A. (1995). The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55, 1937-1940.
129. Ito, N., Shirai, T., Tagawa, Y., Nakamura, A., and Fukushima, S. (1988). Variation in tumor yield in the prostate and other target organs of the rat in response to varied dosage and duration of administration of 3,2′ -dimethyl-4-aminobiphenyl. Cancer Res. 48, 4629-4632.
130. Jackson, M. A., Kovi, J., Heshmat, M. Y., Jones, G. W., Rao, M. S., and Ahluwalia, B. S. (1981). Factors involved in the high incidence of prostatic cancer among American blacks. Prog. Clin. Biol. Res. 53, 111-132.
131. Jackson, M. W., Bentel, J. M., and Tilley, W. D. (1997). Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol. 157, 2323-2328.
132. Johnson, D. E., and Williams, L. T. (1993). Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60, 1-41.
133. Jung-Testas, I., Groyer, M. T., Bruner-Lorand, J., Hechter, O., Baulieu, E. E., and Robel, P. (1981). Androgen and estrogen receptors in rat ventral prostate epithelium and stroma. Endocrinology 109, 1287-1289.
134. Kasai, S., Sugimura, K., Matsumoto, K., Nishi, N., Kishimoto, T., and Nakamura, T. (1996). Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth. Biochem. Biophys. Res. Commun. 228, 646-652.
135. Katayama, S., Fiala, E., Reddy, B. S., Rivenson, A., Silverman, J., Williams, G. M., and Weisburger, J. H. (1982). Prostate adenocarcinoma in rats: Induction by 3,2′-dimethyl-4-aminobiphenyl. J. Natl. Cancer Inst. 68, 867-873.
136. Kelly, R. J., Ernst, L. K., Larsen, R. D., Bryant, J. G., Robinson, J. S., and Lowe, J. B. (1994). Molecular basis for H blood group deficiency in Bombay (Oh) and para-Bombay individuals. Proc. Natl. Acad. Sci. USA 91, 5843-5847.
137. Kim, I. Y., Ahn, H. J., Zelner, D. J., Park, L., Sensibar, J. A., and Lee, C. (1996). Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Mol. Endocrinol. 10, 107-115.
138. Kim, M. J., Bhatia-Gaur, R., Banach-Petrosky, W. A., Desai, N., Wang, Y., Hayward, S. W., Cunha, G. R., Cardiff, R. D., Shen, M. M., and Abate-Shen, C. (2002a). Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62, 2999-3004.
139. Kim, M. J., Cardiff, R. D., Desai, N., Banach-Petrosky, W. A., Parsons, R., Shen, M. M., and Abate-Shen, C. (2002b). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99, 2884-2889.
140. Kimura, K., Markowski, M., Bowen, C., and Gelmann, E. P. (2001). Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 61, 5611-5618.
141. Kleinerman, D. I., Troncoso, P., Lin, S. H., Pisters, L. L., Sherwood, E. R., Brooks, T., von Eschenbach, A. C., and Hsieh, J. T. (1995). Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: Implication as a tumor suppressor. Cancer Res. 55, 1215-1220.
142. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O. P. (1997). Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319.
143. Kok, K., Naylor, S. L., and Buys, C. H. (1997). Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv. Cancer Res. 71, 27-92.
144. Kolonel, L. N. (1980). Cancer patterns of four ethnic groups in Hawaii. J. Natl. Cancer Inst. 65, 1127-1139.
145. Kolonel, L. N. (2001). Fat, meat, and prostate cancer. Epidemiol. Rev. 23, 72-81.
146. Kolonel, L. N., Nomura, A. M., and Cooney, R. V. (1999). Dietary fat and prostate cancer: Current status. J. Natl. Cancer Inst. 91, 414-428.
147. Kretzschmar, M., and Massague, J. (1998). SMADs: Mediators and regulators of TGF-beta signaling. Curr. Opin. Genet. Dev. 8, 103-111.
148. Krill, D., Shuman, M., Thompson, M. T., Becich, M. J., and Strom, S. C. (1997). A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology 49, 981-988.
149. Kristal, A. R., Cohen, J. H., Qu, P., and Stanford, J. L. (2002). Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 719-725.
150. Krumlauf, R. (1994). Hox genes in vertebrate development. Cell 78, 191-201.
151. Kubota, Y., Fujinami, K., Uemura, H., Dobashi, Y., Miyamoto, H., Iwasaki, Y., Kitamura, H., and Shuin, T. (1995). Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27, 314-320.
152. Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., and Ittmann, M. (2001). Haplo insufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98, 11563-11568.
153. Langlands, K., Down, G. A., and Kealey, T. (2000). Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. Cancer Res. 60, 5929-5933.
154. Lara, P. N., Jr., Kung, H. J., Gumerlock, P. H., and Meyers, F. J. (1999). Molecular biology of prostate carcinogenesis. Crit. Rev. Oncol. Hematol. 32, 197-208.
155. Latil, A., Bieche, I., Vidaud, D., Lidereau, R., Berthon, P., Cussenot, O., and Vidaud, M. (2001). Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61, 1919-1926.
156. Lau, K. M., Leav, I., and Ho, S. M. (1998). Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology 139, 424-427.
157. Lau, K. M., LaSpina, M., Long, J., and Ho, S. M. (2000). Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res. 60, 3175-3182.
158. Leav, I., Ho, S. M., Ofner, P., Merk, F. B., Kwan, P. W., and Damassa, D. (1988). Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst. 80, 1045-1053.
159. Leav, I., Merk, F. B., Kwan, P. W., and Ho, S. M. (1989). Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15, 23-40.
160. Leav, I., Lau, K. M., Adams, J. Y., McNeal, J. E., Taplin, M. E., Wang, J., Singh, H., and Ho, S. M. (2001). Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159, 79-92.
161. Lerman, M. I., and Minna, J. D. (2000). The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 60, 6116-6133.
162. Lesko, S. M., Rosenberg, L., and Shapiro, S. (1996). Family history and prostate cancer risk. Am. J. Epidemiol. 144, 1041-1047.
163. Leung, G., Benzie, I. F., Cheung, A., Tsao, S. W., and Wong, Y. C. (2002). No effect of a high-fat diet on promotion of sex hormone-induced prostate and mammary carcinogenesis in the Noble rat model. Br. J. Nutr. 88, 399-409.
164. Leung, H. Y., Dickson, C., Robson, C. N., and Neal, D. E. (1996). Over-expression of fibroblast growth factor-8 in human prostate cancer. Oncogene 12, 1833-1835.
165. Leung, H. Y., Mehta, P., Gray, L. B., Collins, A. T., Robson, C. N., and Neal, D. E. (1997). Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15, 1115-1120.
166. Li, L. C., Chui, R., Nakajima, K., Oh, B. R., Au, H. C., and Dahiya, R. (2000). Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res. 60, 702-706.
167. Lin, C. Q., Singh, J., Murata, K., Itahana, Y., Parrinello, S., Liang, S. H., Gillett, C. E., Campisi, J., and Desprez, P. Y. (2000). A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 60, 1332-1340.
168. Ling, M. T., Wang, X., Ouyang, X. S., Lee, T. K., Fan, T. Y., Xu, K., Tsao, S. W., and Wong, Y. C. (2002a). Activation of MAPK signaling pathway is essential for Id-I induced serum independent prostate cancer cell growth. Oncogene 21, 8498-8505.
169. Ling, M. T., Wang, X., Tsao, S. W., and Wong, Y. C. (2002b). Down-regulation of Id-1 expression is associated with TGF beta 1-induced growth arrest in prostate epithelial cells. Biochim. Biophys. Acta 1570, 145-152.
170. Liu, A. Y. (1994). Expression of CD44 in prostate cancer cells. Cancer Lett. 76, 63-69.
171. Lookingbill, D. P., Demers, L. M., Wang, C., Leung, A., Rittmaster, R. S., and Santen, R. J. (1991). Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Endocrinol. Metab. 72, 1242-1248.
172. Lopaczynski, W., Hruszkewycz, A. M., and Lieberman, R. (2001). Preprostatectomy: A clinical model to study stromal-epithelial interactions. Urology 57, 194-199.
173. Lu, S., Tsai, S. Y., and Tsai, M. J. (1997). Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CK1 p16 genes. Cancer Res. 57, 4511-4516.
174. Lu, S., Liu, M., Epner, D. E., Tsai, S. Y., and Tsai, M. J. (1999). Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol. Endocrinol. 13, 376-384.
175. Madaan, S., Abel, P. D., Chaudhary, K. S., Hewitt, R., Stott, M. A., Stamp, G. W., and Lalani, E. N. (2000). Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int. 86, 736-741.
176. Maffini, M. V., Geck, P., Powell, C. E., Sonnenschein, C., and Soto, A. M. (2002). Mechanism of androgen action on cell proliferation: AS3 protein as a mediator of proliferative arrest in the rat prostate. Endocrinology 143, 2708-2714.
177. Mahmoudi, T., and Verrijzer, C. P. (2001). Chromatin silencing and activation by Polycomb and trithorax group proteins. Oncogene 20, 3055-3066.
178. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C. Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. (1997). A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 57, 1020-1022.
179. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., and Reichardt, J. K. (1999). Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975-978.
180. Marengo, S. R., Sikes, R. A., Anezinis, P., Chang, S. M., and Chung, L. W. (1997). Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol. Carcinog. 19, 165-175.
181. Marker, P. C., Stephan, J. P., Lee, J., Bald, L., Mather, J. P., and Cunha, G. R. (2001). Fucosyltransferase and H-type complex carbohydrates modulate epithelial cell proliferation during prostatic branching morphogenesis. Dev. Biol. 233, 95-108.
182. Markides, C. S., Roy, D., and Liehr, J. G. (1998). Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. Arch. Biochem. Biophys. 360, 105-112.
183. Maroulakou, I. G., Anver, M., Garrett, L., and Green, J. E. (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91, 11236-11240.
184. Maruyama, H., Kleeff, J., Wildi, S., Friess, H., Buchler, M. W., Israel, M. A., and Korc, M. (1999). Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am. J. Pathol. 155, 815-822.
185. Massague, J. (1990). The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6, 597-641.
186. Matsubara, A., Kan, M., Feng, S., and McKeehan, W. L. (1998). Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res. 58, 1509-1514.
187. Matsumoto, K., and Nakamura, T. (1997). HGF: Its organotrophic role and therapeutic potential. Ciba Found. Symp. 212, 198-211.
188. McGarvey, T. W., and Steams, M. E. (1995). Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp. Mol. Pathol. 63, 52-62.
189. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. (1999). Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291-4296.
190. McNeal, J. E. (1988). Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin. Ultrasound CT MRI 9, 329-334.
191. Meikle, A. W., and Stanish, W. M. (1982). Familial prostatic cancer risk and low testosterone. J. Clin. Endocrinol. Metab. 54, 1104-1108.
192. Mettlin, C. J., Murphy, G. P., Ho, R., and Menck, H. R. (1996). The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 77, 2162-2166.
193. Miki, T., Bottaro, D. P., Fleming, T. P., Smith, C. L., Burgess, W. H., Chan, A. M., and Aaronson, S. A. (1992). Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. USA 89, 246-250.
194. Moeller, H., Blank, B., Lander, K., and Mates, G. (1987). Ontogeny of the androgen receptor in rat ventral prostate during sexual development. Res. Exp. Med. (Berl.) 187, 287-294.
195. Mondino, A., Giordano, S., and Comoglio, P. M. (1991). Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor). Mol. Cell. Biol. 11, 6084-6092.
196. Montie, J. E., and Pienta, K. J. (1994). Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 43, 892-899.
197. Morales, C. R., Zhao, Q., El Alfy, M., and Suzuki, K. (2000). Targeted disruption of the mouse prosaposin gene affects the development of the prostate gland and other male reproductive organs. J. Androl. 21, 765-775.
198. Morgan, B. A., and Tabin, C. (1994). Hox genes and growth: Early and late roles in limb bud morphogenesis. Dev. Suppl. 181-186.
199. Morris, M. J., Reuter, V. E., Kelly, W. K., Slovin, S. F., Kenneson, K., Verbel, D., Osman, I., and Scher, H. I. (2002). HER-2 profiling and targeting in prostate carcinoma. Cancer 94, 980-986.
200. Morton, R. A., Jr. (1994). Racial differences in adenocarcinoma of the prostate in North American men. Urology 44, 637-645.
201. Moustakas, A., Pardali, K., Gaal, A., and Heldin, C. H. (2002). Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol. Lett. 82, 85-91.
202. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K., and Shimizu, S. (1989). Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443.
203. Nakamura, T., Hillova, J., Mariage-Samson, R., Onno, M., Huebner, K., Cannizzaro, L. A., Boghosian-Sell, L., Croce, C. M., and Hill, M. (1992). A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells. Oncogene 7, 733-741.
204. Nakamura, T., Matsumoto, K., Kiritoshi, A., Tano, Y., and Nakamura, T. (1997). Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res. 57, 3305-3313.
205. Narod, S. A., Dupont, A., Cusan, L., Diamond, P., Gomez, J. L., Suburu, R., and Labrie, F. (1995). The impact of family history on early detection of prostate cancer. Nat. Med. 1, 99-101.
206. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85, 1657-1669.
207. Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., and Lin, B. (2002). The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. USA 99, 11890-11895.
208. Nemeth, J. A., Sensibar, J. A., White, R. R., Zelner, D. J., Kim, I. Y., and Lee, C. (1997). Prostatic ductal system in rats: Tissue-specific expression and regional variation in stromal distribution of transforming growth factor-beta 1. Prostate 33, 64-71.
209. Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y., and Kraft, A. S. (2001). Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276, 10767-10774.
210. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22.
211. Neumaier, M., Paululat, S., Chan, A., Matthaes, P., and Wagener, C. (1993). Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc. Natl. Acad. Sci. USA 90, 10744-10748.
212. Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L., and Pollak, M. (2001). In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61, 6276-6280.
213. Noble, R. L. (1977). The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 37, 1929-1933.
214. Nollau, P., Scheller, H., Kona-Horstmann, M., Rohde, S., Hagenmuller, F., Wagener, C., and Neumaier, M. (1997). Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Cancer Res. 57, 2354-2357.
215. Ohtani, N., Zebedee, Z., Huot, T. J., Stinson, J. A., Sugimoto, M., Ohashi, Y., Sharrocks, A. D., Peters, G., and Hara, E. (2001). Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409, 1067-1070.
216. Okadome, T., Yamashita, H., Franzen, P., Moren, A., Heldin, C. H., and Miyazono, K. (1994). Distinct roles of the intracellular domains of transforming growth factor-beta type I and type II receptors in signal transduction. J. Biol. Chem. 269, 30753-30756.
217. Ostrander, E. A., and Stanford, J. L. (2000). Genetics of prostate cancer: Too many loci, too few genes. Am. J. Hum. Genet. 67, 1367-1375.
218. Ouyang, X. S., Wang, X., Lee, D. T., Tsao, S. W., and Wong, Y. C. (2001). Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 22, 965-973.
219. Ouyang, X. S., Wang, X., Lee, D. T., Tsao, S. W., and Wong, Y. C. (2002a). Over expression of ID-1 in prostate cancer. J. Urol. 167, 2598-2602.
220. Ouyang, X. S., Wang, X., Ling, M. T., Wong, H. L., Tsao, S. W., and Wong, Y. C. (2002b). Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis 23, 721-725.
221. Park, M., Dean, M., Kaul, K., Braun, M. J., Gonda, M. A., and Vande-Woude, G. (1987). Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA 84, 6379-6383.
222. Pei, L., Peng, Y., Yang, Y., Ling, X. B., Van Eyndhoven, W. G., Nguyen, K. C., Rubin, M., Hoey, T., Powers, S., and Li, J. (2002). PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res. 62, 5420-5424.
223. Piau, J. P., Labarriere, N., Dabouis, G., and Denis, M. G. (1994). Evidence for two distinct alpha(1,2)-fucosyltransferase genes differentially expressed throughout the rat colon. Biochem. J. 300, 623-626.
224. Platz, E. A., Rimm, E. B., Willett, W. C., Kantoff, P. W., and Giovannucci, E. (2000). Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J. Natl. Cancer Inst. 92, 2009-2017.
225. Podlasek, C. A., Duboule, D., and Bushman, W. (1997). Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev. Dyn. 208, 454-465.
226. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., and Parsons, R. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96, 1563-1568.
227. Poltorak, Z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, I., Keshet, E., and Neufeld, G. (1997). VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272, 7151-7158.
228. Potten, C. S., and Loeffler, M. (1990). Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 110, 1001-1020.
229. Pour, P. M., and Stepan, K. (1987). Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl)amine. Cancer Res. 47, 5699-5706.
230. Prescott, J. L., Blok, L., and Tindall, D. J. (1998). Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35, 71-80.
231. Prins, G. S., and Birch, L. (1995). The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 136, 1303-1314.
232. Prins, G. S., and Birch, L. (1997). Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 138, 1801-1809.
233. Prins, G. S., Birch, L., and Greene, G. L. (1991). Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 129, 3187-3199.
234. Prins, G. S., Jung, M. H., Vellanoweth, R. L., Chatterjee, B., and Roy, A. K. (1996). Age-dependent expression of the androgen receptor gene in the prostate and its implication in glandular differentiation and hyperplasia. Dev. Genet. 18, 99-106.
235. Pylkkanen, L., Makela, S., Valve, E., Harkonen, P., Toikkanen, S., and Santti, R. (1993). Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice. J. Urol. 149, 1593-1601.
236. Qiu, Y., Ravi, L., and Kung, H. J. (1998). Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393, 83-85.
237. Raghow, S., Hooshdaran, M. Z., Katiyar, S., and Steiner, M. S. (2002). Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62, 1370-1376.
238. Rajah, T. T., and Pento, J. T. (1995). The mutagenic potential of antiestrogens at the HPRT locus in V79 cells. Res. Commun. Mol. Pathol. Pharmacol. 89, 85-92.
239. Ravindranath, N., Wion, D., Brachet, P., and Djakiew, D. (2001). Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl. 22, 432-443.
240. Reichardt, J. K., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C., and Ross, R. K. (1995). Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res. 55, 3973-3975.
241. Rhim, J. S. (2001). Molecular and genetic mechanisms of prostate cancer. Radiat. Res. 155, 128-132.
242. Risbridger, G., Wang, H., Young, P., Kurita, T., Wang, Y. Z., Lubahn, D., Gustafsson, J. A., Cunha, G., and Wong, Y. Z. (2001a). Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev. Biol. 229, 432-442.
243. Risbridger, G. P., Wang, H., Frydenberg, M., and Cunha, G. (2001b). The metaplastic effects of estrogen on mouse prostate epithelium: Proliferation of cells with basal cell phenotype. Endocrinology 142, 2443-2450.
244. Rodrigues, G. A., Naujokas, M. A., and Park, M. (1991). Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol. Cell. Biol. 11, 2962-2970.
245. Rosen, E. M., Nigam, S. K., and Goldberg, I. D. (1994). Scatter factor and the c-met receptor: A paradigm for mesenchymal/epithelial interaction. J. Cell Biol. 127, 1783-1787.
246. Rosen, E. M., Lamszus, K., Laterra, J., Polverini, P. J., Rubin, J. S., and Goldberg, I. D. (1997). HGF/SF in angiogenesis. Ciba Found. Symp. 212, 215-226.
247. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D., and Shapiro, S. (1991). A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 83, 355-358.
248. Ross, R., Bernstein, L., Judd, H., Hanisch, R., Pike, M., and Henderson, B. (1986). Serum testosterone levels in healthy young black and white men. J. Natl. Cancer Inst. 76, 45-48.
249. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. (1992). 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339, 887-889.
250. Ross, R. K., Pike, M. C., Coetzee, G. A., Reichardt, J. K., Yu, M. C., Feigelson, H., Stanczyk, F. Z., Kolonel, L. N., and Henderson, B. E. (1998). Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res. 58, 4497-4504.
251. Rowley, D. R. (1998). What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 17, 411-419.
252. Ruan, W., Powell-Braxton, L., Kopchick, J. J., and Kleinberg, D. L. (1999). Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140, 1984-1989.
253. Rubin, J. S., Bottaro, D. P., Chedid, M., Miki, T., Ron, D., Cunha, G. R., and Finch, P. W. (1995). Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. EXS 74, 191-214.
254. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schroder, F. H., and van der Kwast, T. H. (1994). Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 144, 735-746.
255. Schuurman, A. G., van den Brandt, P. A., Dorant, E., Brants, H. A., and Goldbohm, R. A. (1999). Association of energy and fat intake with prostate carcinoma risk: Results from The Netherlands Cohort Study. Cancer 86, 1019-1027.
256. Scott, M. P. (1992). Vertebrate homeobox gene nomenclature. Cell 71, 551-553.
257. Sekido, Y., Ahmadian, M., Wistuba, I. I., Latif, F., Bader, S., Wei, M. H., Duh, F. M., Gazdar, A. F., Lerman, M. I., and Minna, J. D. (1998). Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16, 3151-3157.
258. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
259. Shannon, J. M., and Cunha, G. R. (1984). Characterization of androgen binding and deoxyribonucleic acid synthesis in prostate-like structures induced in the urothelium of testicular feminized (Tfm/Y) mice. Biol. Reprod. 31, 175-183.
260. Shariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., and Slawin, K. M. (2001). Preoperative plasma levels of transforming growth factor beta(1) [TGF-beta(1)] strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19, 2856-2864.
261. Shibata, A., and Whittemore, A. S. (1997). Genetic predisposition to prostate cancer: Possible explanations for ethnic differences in risk. Prostate 32, 65-72.
262. Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. (1990). Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5, 519-524.
263. Shike, M., Latkany, L., Riedel, E., Fleisher, M., Schatzkin, A., Lanza, E., Corle, D., and Begg, C. B. (2002). Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: Results from a randomized trial. J. Clin. Oncol. 20, 3592-3598.
264. Shirai, T., Tamano, S., Kato, T., Iwasaki, S., Takahashi, S., and Ito, N. (1991). Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2′-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res. 51, 1264-1269.
265. Shirai, T., Yamamoto, A., Imaida, K., Tamano, S., Mori, T., and Hasegawa, R. (1992). Lack of synergism among DMAB, BOP, and MNU in induction of carcinomas of the rat ventral prostate. Teratog. Carcinog. Mutagen. 12, 71-77.
266. Shirai, T., Tada, M., Kojima, M., Hasegawa, R., Masui, T., and Ito, N. (1994). DNA adducts in target and nontarget tissues of 3,2′ -dimethyl-4-aminobiphenyl in rats. Environ. Health Perspect. 102(Suppl. 6), 167-172.
267. Shirai, T., Sano, M., Tamano, S., Takahashi, S., Hirose, M., Futakuchi, M., Hasegawa, R., Imaida, K., Matsumoto, K., Wakabayashi, K., Sugimura, T., and Ito, N. (1997a). The prostate: A target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res. 57, 195-198.
268. Shirai, T., Takahashi, S., and Tamano, S. (1997b). Prenoplasia and neoplasia of the rat male genital tract In (P. Bannash and W. Gosner, Eds.), "Pathology of Neoplasia and Preneoplasia in Rodents" pp. 141-162, EULEP color Atlas, Schattauer, New York.
269. Signoretti, S., Waltregny, D., Dilks, J., Isaac, B., Lin, D., Garraway, L., Yang, A., Montironi, R., McKeon, F., and Loda, M. (2000). p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 157, 1769-1775.
270. Simental, J. A., Sar, M., Lane, M. V., French, F. S., and Wilson, E. M. (1991). Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. 266, 510-518.
271. Smith, J. R., Freije, D., Carpten, J. D., Gronberg, H., Xu, J., Isaacs, S. D., Brownstein, M. J., Bova, G. S., Guo, H., Bujnovszky, P., Nusskern, D. R., Damber, J. E., Bergh, A., Emanuelsson, M., Kallioniemi, O. P., Walker-Daniels, J., Bailey-Wilson, J. E., Beaty, T. H., Meyers, D. A., Walsh, P. C., Collins, F. S., Trent, J. M., and Isaacs, W. B. (1996). Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274, 1371-1374.
272. Soderkvist, P., Poellinger, L., and Gustafsson, J. A. (1986). Carcinogen-binding proteins in the rat ventral prostate: Specific and nonspecific high-affinity binding sites for benzo(a)pyrene, 3-methylcholanthrene, and 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 46, 651-657.
273. Soker, S., Kaefer, M., Johnson, M., Klagsbrun, M., Atala, A., and Freeman, M. R. (2001). Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am. J. Pathol. 159, 651-659.
274. Song, Z., Wu, X., Powell, W. C., Cardiff, R. D., Cohen, M. B., Tin, R. T., Matusik, R. J., Miller, G. J., and Roy-Burman, P. (2002). Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: A new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 62, 5096-5105.
275. Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B., and Walsh, P. C. (1990). Family history and the risk of prostate cancer. Prostate 17, 337-347.
276. Sugimura, Y., Cunha, G. R., and Donjacour, A. A. (1986). Morphogenesis of ductal networks in the mouse prostate. Biol. Reprod. 34, 961-971.
277. Sugimura, Y., Foster, B. A., Hom, Y. K., Lipschutz, J. H., Rubin, J. S., Finch, P. W., Aaronson, S. A., Hayashi, N., Kawamura, J., and Cunha, G. R. (1996). Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int. J. Dev. Biol. 40, 941-951.
278. Takeda, H., and Chang, C. (1991). Immunohistochemical and in-situ hybridization analysis of androgen receptor expression during the development of the mouse prostate gland. J. Endocrinol. 129, 83-89.
279. Tam, N. N., Chung, S. S., Lee, D. T., and Wong, Y. C. (2000). Aberrant expression of hepatocyte growth factor and its receptor, c-Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat. Carcinogenesis 21, 2183-2191.
280. Tanaka, M., Komuro, I., Inagaki, H., Jenkins, N. A., Copeland, N. G., and Izumo, S. (2000). Nkx3.1, a murine homolog of Drosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev. Dyn. 219, 248-260.
281. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398.
282. Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., Camp, N. J., Carillo, A. R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J. M., Frank, D., Frye, C., Ghaffari, S., Gupte, J. S., Hu, R., Iliev, D., Janecki, T., Kort, E. N., Laity, K. E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K. T., Reid, J. E., Richards, S., Schroeder, M., Smith, R., Snyder, S. C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A. M., Labrie, F., Skolnick, M. H., Neuhausen, S., Rommens, J., and Cannon-Albright, L. A. (2001). A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27, 172-180.
283. Tennant, M. K., Thrasher, J. B., Twomey, P. A., Birnbaum, R. S., and Plymate, S. R. (1996a). Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J. Clin. Endocrinol. Metab. 81, 3783-3792.
284. Tennant, M. K., Thrasher, J. B., Twomey, P. A., Drivdahl, R. H., Birnbaum, R. S., and Plymate, S. R. (1996b). Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 81, 3774-3782.
285. Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L., and Shows, T. B. (1991). Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677-1683.
286. Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586.
287. Thompson, T. C., Timme, T. L., Kadmon, D., Park, S. H., Egawa, S., and Yoshida, K. (1993). Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol. Carcinog. 7, 165-179.
288. Timme, T. L., Truong, L. D., Merz, V. W., Krebs, T., Kadmon, D., Flanders, K. C., Park, S. H., and Thompson, T. C. (1994). Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 134, 1039-1045.
289. Timme, T. L., Truong, L. D., Slawin, K. M., Kadmon, D., Park, S. H., and Thompson, T. C. (1995). Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc. Res. Tech. 30, 333-341.
290. Timme, T. L., Yang, G., Rogers, E., Kadmon, D., Morganstern, J. P., Park, S. H., and Thompson, T. C. (1996). Retroviral transduction of transforming growth factor-beta induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab. Invest. 74, 747-760.
291. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954.
292. Tjandrawinata, R. R., Dahiya, R., and Hughes-Fulford, M. (1997). Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br. J. Cancer 75, 1111-1118.
293. Trapman, J. (2001). Molecular mechanisms of prostate cancer. Eur. J. Cancer 37(Suppl. 7), S119-S125.
294. Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., and Sidransky, D. (1998). A new human p53 homologue. Nat. Med. 4, 747-748.
295. Tsujii, M., and DuBois, R. N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501.
296. Tsujii, M., Kawano, S., and DuBois, R. N. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA 94, 3336-3340.
297. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716.
298. Tsutsui, T., Maizumi, H., McLachlan, J. A., and Barrett, J. C. (1983). Aneuploidy induction and cell transformation by diethylstilbestrol: A possible chromosomal mechanism in carcinogenesis. Cancer Res. 43, 3814-3821.
299. van der Kwast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C., Mulder, E., Boersma, W., and Trapman, J. (1991). Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 48, 189-193.
300. van der Kwast, T. H., Labrie, F., and Tetu, B. (1999). Persistence of high-grade prostatic intraepithelial neoplasia under combined androgen blockade therapy. Hum. Pathol. 30, 1503-1507.
301. van Leenders, G., van Balken, B., Aalders, T., Hulsbergen-van de Kaa, C., Ruiter, D., and Schalken, J. (2002). Intermediate cells in normal and malignant prostate epithelium express c-MET: Implications for prostate cancer invasion. Prostate 51, 98-107.
302. Vande-Woude, G. F., Jeffers, M., Cortner, J., Alvord, G., Tsarfaty, I., and Resau, J. (1997). Met-HGF/SF: Tumorigenesis, invasion and metastasis. Ciba Found. Symp. 212, 119-130.
303. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G., Otte, A. P., Rubin, M. A., and Chinnaiyan, A. M. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629.
304. Verhagen, A. P., Ramaekers, F. C., Aalders, T. W., Schaafsma, H. E., Debruyne, F. M., and Schalken, J. A. (1992). Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 52, 6182-6187.
305. Verhoeven, D. T., Goldbohm, R. A., van Poppel, G., Verhagen, H., and van
306. Verhoeven, D. T., Verhagen, H., Goldbohm, R. A., van den Brandt, P. A., and van Poppel, G. (1997). A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Chem. Biol. Interact. 103, 79-129.
307. Vocke, C. D., Pozzatti, R. O., Bostwick, D. G., Florence, C. D., Jennings, S. B., Strup, S. E., Duray, P. H., Liotta, L. A., Emmert-Buck, M. R., and Linehan, W. M. (1996). Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 56, 2411-2416.
308. Voeller, H. J., Augustus, M., Madike, V., Bova, G. S., Carter, K. C., and Gelmann, E. P. (1997). Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57, 4455-4459.
309. Volpert, O., Luo, W., Liu, T. J., Estrera, V. T., Logothetis, C., and Lin, S. H. (2002). Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J. Biol. Chem. 277, 35696-35702.
310. Wang, Y., Hayward, S., Cao, M., Thayer, K., and Cunha, G. (2001). Cell differentiation lineage in the prostate. Differentiation 68, 270-279.
311. Wang, Y. Z., and Wong, Y. C. (1997). Oncogenes and tumor suppressor genes in prostate cancer: A review. Urol. Oncol. 3, 41-46.
312. Wang, Y. Z., and Wong, Y. C. (1998). Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 35, 165-177.
313. Weihua, Z., Makela, S., Andersson, L. C., Salmi, S., Saji, S., Webster, J. I., Jensen, E. V., Nilsson, S., Warner, M., and Gustafsson, J. A. (2001). A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. USA 98, 6330-6335.
314. Wernert, N., Seitz, G., and Achtstatter, T. (1987). Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol. Res. Pract. 182, 617-626.
315. Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., and Sawyers, C. L. (1998). Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95, 5246-5250.
316. Widmark, E. (1939). Presence of cancer producing subtances in roasted food. Nature 143, 984.
317. Wieser, R., Wrana, J. L., and Massague, J. (1995). GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J. 14, 2199-2208.
318. Wikstrom, P., Stattin, P., Franck-Lissbrant, I., Damber, J. E., and Bergh, A. (1998). Transforming growth factor beta 1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37, 19-29.
319. Wistuba, I. I., Behrens, C., Virmani, A. K., Mele, G., Milchgrub, S., Girard, L., Fondon, J. W., III, Garner, H. R., McKay, B., Latif, F., Lerman, M. I., Lam, S., Gazdar, A. F., and Minna, J. D. (2000). High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60, 1949-1960.
320. Wong, Y. C., and Tam, N. N. (2002). Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Differentiation 70, 633-645.
321. Wong, Y. C., and Wang, Y. Z. (2000). Growth factors and epithelial-stromal interactions in prostate cancer development. Int. Rev. Cytol. 199, 65-116.
322. Wong, Y. C., Xie, W., and Tsao, S. W. (2000). Structural changes and alteration in expression of TGF-beta 1 and its receptors in prostatic intraepithelial neoplasia (PIN) in the ventral prostate of noble rats. Prostate 45, 289-298.
323. Wrana, J. L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X. F., and Massague, J. (1992). TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003-1014.
324. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347.
325. Xie, W., Wong, Y. C., and Tsao, S. W. (2000). Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. Prostate 44, 31-39.
326. Xu, J., Meyers, D., Freije, D., Isaacs, S., Wiley, K., Nusskern, D., Ewing, C., Wilkens, E., Bujnovszky, P., Bova, G. S., Walsh, P., Isaacs, W., Schleutker, J., Matikainen, M., Tammela, T., Visakorpi, T., Kallioniemi, O. P., Berry, R., Schaid, D., French, A., McDonnell, S., Schroeder, J., Blute, M., Thibodeau, S., and Trent, J., et al. (1998). Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 20, 175-179.
327. Xu, J., Zheng, S. L., Chang, B., Smith, J. R., Carpten, J. D., Stine, O. C., Isaacs, S. D., Wiley, K. E., Henning, L., Ewing, C., Bujnovszky, P., Bleeker, E. R., Walsh, P. C., Trent, J. M., Meyers, D. A., and Isaacs, W. B. (2001a). Linkage of prostate cancer susceptibility loci to chromosome 1. Hum. Genet. 108, 335-345.
328. Xu, J., Zheng, S. L., Hawkins, G. A., Faith, D. A., Kelly, B., Isaacs, S. D., Wiley, K. E., Chang, B., Ewing, C. M., Bujnovszky, P., Carpten, J. D., Bleecker, E. R., Walsh, P. C., Trent, J. M., Meyers, D. A., and Isaacs, W. B. (2001b). Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am. J. Hum. Genet. 69, 341-350.
329. Xue, Y., Smedts, F., Debruyne, F. M., de la Rosette, J. J., and Schalken, J. A. (1998). Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 34, 292-301.
330. Yadollahi-Farsani, M., Gooderham, N. J., Davies, D. S., and Boobis, A. R. (1996). Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine(PhIP) at the Chinese hamsters hprt locus. Carcinogenesis 17, 617-624.
331. Yan, G., Fukabori, Y., Nikolaropoulos, S., Wang, F., and McKeehan, W. L. (1992). Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol. Endocrinol. 6, 2123-2128.
332. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W. L. (1993). Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol. 13, 4513-4522.
333. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305-316.
334. Yang, E. Y., and Moses, H. L. (1990). Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol. 111, 731-741.
335. Yoshimura, R., Sano, H., Masuda, C., Kawamura, M., Tsubouchi, Y., Chargui, J., Yoshimura, N., Hla, T., and Wada, S. (2000). Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89, 589-596.
336. Yuan, X. J., and Whang, Y. E. (2002). PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21, 319-327.
337. Zha, S., Gage, W. R., Sauvageot, J., Saria, E. A., Putzi, M. J., Ewing, C. M., Faith, D. A., Nelson, W. G., De Marzo, A. M., and Isaacs, W. B. (2001). Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61, 8617-8623.
338. Zhang, X., Chen, M. W., Ng, A., Ng, P. Y., Lee, C., Rubin, M., Olsson, C. A., and Buttyan, R. (1997). Abnormal prostate development in C3(1)-bcl-2 transgenic mice. Prostate 32, 16-26.
339. Zhau, H. E., Pisters, L. L., Hall, M. C., Zhao, L. S., Troncoso, P., Pollack, A., and Chung, L. W. (1994). Biomarkers associated with prostate cancer progression. J. Cell Biochem. Suppl. 19, 208-216.
340. Zhu, H., Boobis, A. R., and Gooderham, N. J. (2000). The food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine activates S-phase checkpoint and apoptosis, and induces gene mutation in human lymphoblastoid TK6 cells. Cancer Res. 60, 1283-1289.